Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

GenixPharmaceucticals Corporation

Healthcare CA GENX

0.02CAD
0.00(0%)

Last update at 2026-06-22T13:30:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.020.04
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap1.22M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.12484M
  • Revenue TTM0.00007M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.18299M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Income before tax -0.33505M -0.07320M -4.39557M -1.07400M -1.65252M
Minority interest - - - - -
Net income -0.33505M -0.07320M -4.39557M -1.07400M -1.65252M
Selling general administrative 0.11M 0.17M 0.28M 0.43M 1.12M
Selling and marketing expenses - - - - -
Gross profit 0.00000M 0.00130M 0.00326M - -
Reconciled depreciation 0.00113M 0.00113M 0.55M 0.56M 0.54M
Ebit - - - -0.99843M -1.61037M
Ebitda - - - -0.49769M -1.11240M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -0.15328M -0.24100M -0.88089M -1.03122M -1.65493M
Other operating expenses - - - - -
Interest expense 0.17M 0.12M 0.05M 0.01M 0.00351M
Tax provision - - - - -
Interest income 0.00022M 0.00018M 0.00035M 0.00015M 0.00145M
Net interest income -0.17306M -0.12096M -0.05193M -0.01199M -0.00206M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00405M 0.01M 0.00000M 0.00000M
Total operating expenses 0.15M 0.25M 0.89M 1.03M 1.65M
Cost of revenue 0.00000M 0.00275M 0.00908M - -
Total other income expense net -0.00871M 0.29M -3.46275M -0.03080M 0.00447M
Discontinued operations - - - - -
Net income from continuing ops -0.33505M -0.07320M -4.39557M -1.07400M -1.65252M
Net income applicable to common shares - - - -1.07400M -1.65252M
Preferred stock and other adjustments - - - - -
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Total assets 0.05M 0.05M 0.22M 4.25M 4.77M
Intangible assets 0.00001M 0.00677M 0.00791M 4.01M 4.55M
Earning assets - - - - -
Other current assets - - - - -
Total liab 1.47M 1.23M 1.36M 1.05M 0.76M
Total stockholder equity -1.41935M -1.18320M -1.13736M 3.20M 4.01M
Deferred long term liab - - - - -
Other current liab 0.25M 0.24M 0.58M 0.64M 0.66M
Common stock - - - 9.70M 9.70M
Capital stock 9.76M 9.70M 9.70M 9.70M 9.70M
Retained earnings -12.53895M -12.20390M -12.13070M -7.73513M -6.66113M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.04M 0.01M 0.01M 0.00927M 0.14M
Cash and equivalents - - - - -
Total current liabilities 1.47M 1.23M 1.36M 1.05M 0.74M
Current deferred revenue - - - - -
Net debt 1.00M 0.80M 0.50M 0.17M -
Short term debt - - - - -
Short long term debt 1.04M 0.82M 0.51M 0.18M 0.02M
Short long term debt total - - - - -
Other stockholder equity - - - 1.23M 0.97M
Property plant equipment - - - 0.00373M 0.03M
Total current assets 0.05M 0.04M 0.22M 0.24M 0.19M
Long term investments - - - - -
Net tangible assets - - - -0.80947M -0.53456M
Short term investments - - - - -
Net receivables 0.00174M 0.00578M 0.00141M 0.02M 0.00487M
Long term debt - - - - -
Inventory - 0.00000M 0.16M 0.17M 0.00483M
Accounts payable 0.16M 0.15M 0.25M 0.21M 0.01M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00001M 0.00677M 0.00791M 4.01M 4.58M
Capital lease obligations - - 0.00000M 0.00488M 0.03M
Long term debt total - - - - -
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Investments - - 0.00000M -0.00334M -
Change to liabilities - - - 0.18M -0.09352M
Total cashflows from investing activities - - - -0.00334M -0.00334M
Net borrowings 0.06M 0.19M 0.28M 0.15M -0.01400M
Total cash from financing activities 0.16M 0.19M 0.22M 0.09M -0.12948M
Change to operating activities - - - -0.00354M -0.02844M
Net income -0.33505M -0.07320M -4.39557M -1.07400M -1.65252M
Change in cash 0.03M -0.00015M 0.00236M -0.12955M -0.55779M
Begin period cash flow 0.01M 0.01M 0.00927M 0.14M 0.70M
End period cash flow 0.04M 0.01M 0.01M 0.00927M 0.14M
Total cash from operating activities -0.12407M -0.18734M -0.22067M -0.21958M -0.42831M
Issuance of capital stock 0.10M - - - -
Depreciation 0.00113M 0.00113M 0.55M 0.56M 0.54M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.00000M -0.00081M 0.01M -0.16649M -0.00483M
Change to account receivables - - - -0.01163M 0.00304M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - -0.05499M -0.11548M
Change to netincome - - - 0.30M 0.81M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00334M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.03M 0.03M 0.06M -0.00567M -0.12376M
Stock based compensation 0.00000M 0.03M 0.06M 0.26M 0.81M
Other non cash items 0.17M 0.12M 0.05M 0.00861M 0.00198M
Free cash flow -0.12407M -0.18734M -0.22067M -0.22292M -0.42831M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GENX
GenixPharmaceucticals Corporation		 - -% 0.02 - - 17418.86 1.04 32980.85 30.96
RX
Biosyent Inc.		 0.02 0.14% 14.02 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 - -% 0.12 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 - -% 0.50 - - 108.48 4.41 140.29 -4.258
LSL
LSL Pharma Group Inc.		 - -% 0.32 20.75 - 1.88 1.89 2.85 10.19

Reports Covered

Stock Research & News

View All

Profile

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, a dietary supplement to support kidney health; Sucanon, an herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults; and Synthroid, a levothyroxine sodium drug for the treatment of hypothyroidism. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.

GenixPharmaceucticals Corporation

1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9

Key Executives

Name Title Year Born
Mr. Sina Salehi Pirooz CEO & Director NA
Mr. Mahmoud S. Aziz Pres & Director 1958
Mr. Wayne Kent Lee CA, CPA Chief Financial Officer 1968
Mr. Kevin James Bottomley Director of Corp. Devel. & Independent Director NA
Dr. Haofang Song Mang. NA
Ms. Monita Franziska Valeska Faris Company Sec. 1967
Mr. Mahmoud S. Aziz Chairman of the Board & President 1958
Mr. Kevin James Bottomley Director of Corporate Development & Independent Director 1979
Ms. Monita Franziska Valeska Faris Company Secretary 1967
Mr. Kevin James Bottomley Director of Corporate Development & Independent Director 1980

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.